Skip navigation

Emerging Trends, Best Practices and Benchmarking for Managing Risks Associated with Orphan Drug Development and Commercialization

September 11-12, 2019
  • Boston, MA

CBI’s 5th Annual Compliance Congress for Specialty Products is the life science industry’s only conference catered to the unique compliance challenges for specialty pharmaceutical companies pre- and post-commercialization.

While specialty products are immensely valuable to patients, they also bring unprecedented risks for pharmaceutical companies. A comprehensive compliance program is essential to correctly assessing risks, including patient support services, non-promotional activities, third-party relationships and pharmacy contracting. At this highly-rated annual meeting, take the opportunity to identify and address the top risk areas for specialty product manufacturers and compare strategies for promoting a compliant culture within your organization.

Join the Compliance Community for Compelling Discussions On:

  • Recently released guidance from FDA and DOJ
  • Risks associated with Patient Support Services
  • Transforming the internal role of the compliance officer
    from policeman to partner
  • Third party risk management
  • State drug pricing
  • Transparent relationships with patient advocacy groups
    and charitable foundations
  • Nurses educator programs
  • And more!

Previous Attendee Acclaim:

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics

This is the only conference that I am aware of that
focuses on compliance for specialty products. The
unique forum provides a great opportunity to share
best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics

5th Annual Compliance Congress for Specialty Products

Emerging Trends, Best Practices and Benchmarking for Managing Risks Associated with Orphan Drug Development and Commercialization

CBI’s 5th Annual Compliance Congress for Specialty Products is the life science industry’s only conference catered to the unique compliance challenges for specialty pharmaceutical companies pre- and post-commercialization.

While specialty products are immensely valuable to patients, they also bring unprecedented risks for pharmaceutical companies. A comprehensive compliance program is essential to correctly assessing risks, including patient support services, non-promotional activities, third-party relationships and pharmacy contracting. At this highly-rated annual meeting, take the opportunity to identify and address the top risk areas for specialty product manufacturers and compare strategies for promoting a compliant culture within your organization.

Join the Compliance Community for Compelling Discussions On:

  • Recently released guidance from FDA and DOJ
  • Risks associated with Patient Support Services
  • Transforming the internal role of the compliance officer
    from policeman to partner
  • Third party risk management
  • State drug pricing
  • Transparent relationships with patient advocacy groups
    and charitable foundations
  • Nurses educator programs
  • And more!

Previous Attendee Acclaim:

Great information for someone starting out
in specialty pharma.

Associate Director, Compliance, PTC Therapeutics

This is the only conference that I am aware of that
focuses on compliance for specialty products. The
unique forum provides a great opportunity to share
best practices and benchmark programs.

Chief Compliance Officer, Haemonetics

The speaking faculty scope and depth provided an outstanding view of specialty compliance risks
and tools to minimization.

Director, Govt Programs & Commercial Compliance, Prometric Biotherapeutics